GLP-1 / incretin agonist series

GLP-1 / incretinRefresh recommended

GLP-1 receptor agonist chemotypes from exenatide/liraglutide to semaglutide, dual GIP/GLP-1 tirzepatide, triple agonists, and oral small-molecule orforglipron.

Mechanism · GLP-1 / incretin BioMoa · GLP-1 / incretin BioMoa bridge · shared ID

Last analysis: 7/20/2026, 2:08:33 AM · 2 weeks cadence · refresh on /analyze · refresh recommended

Data sources: Catalog seed · ChEMBL · PubChem · ClinicalTrials.gov · FDA/EMA · Investigational
Last updated: 7/20/2026, 2:08:33 AM
Similarity method: Morgan fingerprint, radius 2, 2048 bits, Tanimoto
Verified / known compounds: 8
Exploratory nodes: 1
Abstract scaffolds: 1
Relationship types: Derived (curated) · Fingerprint similarity · Drug-class link

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Spider Web · Flow · Structure table · Compare · SMILES map

Name, 2D structure, SMILES, role, parent, core similarity, and traits. Click a row for details.

Compound	Role	SMILES	Parent	Core sim.	Traits
GLP-1 incretin pharmacophoreAbstract pharmacophoreglp1-incretin-corePage	Scaffold	`N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)…`	—	—	GLP-1 · incretin · core · Shared pharmacophore / core scaffold. Anchor for the GLP-1 / incretin agonist series linea…
Dulaglutide (Trulicity)Verified drugdulaglutidePage	Drug	`N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)…`	GLP-1 incretin pharmacophore	67%i	approved · GLP-1 · peptide · weekly · Approved therapeutic. Dulaglutide (Trulicity) in this family map. · CHEMBL2107876
Exenatide (Byetta / Bydureon)Verified drugexenatidePage	Drug	`N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)…`	GLP-1 incretin pharmacophore	73%i	approved · GLP-1 · peptide · Approved therapeutic. Exenatide (Byetta / Bydureon) in this family map. · CHEMBL1201515 · CID 45588096
Liraglutide (Victoza / Saxenda)Verified drugliraglutidePage	Drug	`N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)…`	GLP-1 incretin pharmacophore	72%i	approved · GLP-1 · peptide · obesity · Approved therapeutic. Liraglutide (Victoza / Saxenda) in this family map. · CHEMBL1201516 · CID 16134956
OrforglipronKnown compoundorforglipronPage	Drug	`CC1=C(C(=O)N2CCCC2)C(=NN1c3ccc(C(=O)O)cc3)…`	GLP-1 incretin pharmacophore	8%i	clinical · GLP-1 · oral · small-molecule · Oral non-peptide small-molecule GLP-1RA — modality bridge like Lipfendra in PCSK9. · CID 166024334
Retatrutide (LY3437943)Known compoundretatrutidePage	Drug	`N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)…`	Tirzepatide (Mounjaro / Zepbound)	52%i	clinical · GLP-1 · GIP · glucagon · triple-agonist · Clinical-stage candidate. Retatrutide (LY3437943) in this family map.
Semaglutide (Ozempic / Wegovy / Rybelsus)Verified drugsemaglutidePage	Drug	`N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)…`	GLP-1 incretin pharmacophore	60%i	approved · GLP-1 · peptide · obesity · oral-tablet · Weekly injectable and oral tablet (Rybelsus) GLP-1RA — metabolic/obesity cornerstone. · CHEMBL3707239 · CID 56843331
Survodutide (BI 456906)Known compoundsurvodutidePage	Drug	`N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)…`	Liraglutide (Victoza / Saxenda)	68%i	clinical · GLP-1 · glucagon · dual-agonist · Clinical-stage candidate. Survodutide (BI 456906) in this family map.
Tirzepatide (Mounjaro / Zepbound)Verified drugtirzepatidePage	Drug	`N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)…`	Semaglutide (Ozempic / Wegovy / Rybelsus)	51%i	approved · GLP-1 · GIP · dual-agonist · obesity · Dual GIP/GLP-1 receptor agonist — next-wave incretin after mono GLP-1RAs. · CID 156588855
Fatty-acid acylated GLP-1 SAR analogExploratory analog (rule-generated)glp1-sar-fatty-acidPage	Derivative	`N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)…`	Semaglutide (Ozempic / Wegovy / Rybelsus)	72%i	SAR · GLP-1 · acylation · SAR exploration node. Derived analog of parent node in GLP-1 / incretin agonist series.

Name	Role	Derived from	Sim. to core	Relations	Tags
Dulaglutide (Trulicity)Verified drug	Drug	GLP-1 incretin pharmacophore	67%i	derived_from: GLP-1 incretin pharmacophore · similar_to: GLP-1 incretin pharmacophore · similar_to: Exenatide (Byetta / Bydureon) · similar_to: Liraglutide (Victoza / Saxenda) · similar_to: Semaglutide (Ozempic / Wegovy / Rybelsus) · similar_to: Tirzepatide (Mounjaro / Zepbound) · similar_to: Retatrutide (LY3437943) · similar_to: Survodutide (BI 456906) · similar_to: Fatty-acid acylated GLP-1 SAR analog	approved, GLP-1, peptide, weekly
Exenatide (Byetta / Bydureon)Verified drug	Drug	GLP-1 incretin pharmacophore	73%i	derived_from: GLP-1 incretin pharmacophore · similar_to: GLP-1 incretin pharmacophore · similar_to: Liraglutide (Victoza / Saxenda) · similar_to: Dulaglutide (Trulicity) · similar_to: Semaglutide (Ozempic / Wegovy / Rybelsus) · similar_to: Tirzepatide (Mounjaro / Zepbound) · similar_to: Retatrutide (LY3437943) · similar_to: Survodutide (BI 456906) · similar_to: Fatty-acid acylated GLP-1 SAR analog	approved, GLP-1, peptide
Fatty-acid acylated GLP-1 SAR analogExploratory analog (rule-generated)	Derivative	Semaglutide (Ozempic / Wegovy / Rybelsus)	72%i	derived_from: Semaglutide (Ozempic / Wegovy / Rybelsus) · similar_to: GLP-1 incretin pharmacophore · similar_to: Exenatide (Byetta / Bydureon) · similar_to: Liraglutide (Victoza / Saxenda) · similar_to: Dulaglutide (Trulicity) · similar_to: Semaglutide (Ozempic / Wegovy / Rybelsus) · similar_to: Tirzepatide (Mounjaro / Zepbound) · similar_to: Retatrutide (LY3437943) · similar_to: Survodutide (BI 456906)	SAR, GLP-1, acylation
GLP-1 incretin pharmacophoreAbstract pharmacophore	Scaffold	—	—	derived_from: Exenatide (Byetta / Bydureon) · derived_from: Dulaglutide (Trulicity) · derived_from: Semaglutide (Ozempic / Wegovy / Rybelsus) · derived_from: Orforglipron · derived_from: Liraglutide (Victoza / Saxenda) · similar_to: Orforglipron · similar_to: Tirzepatide (Mounjaro / Zepbound) · similar_to: Retatrutide (LY3437943) · similar_to: Survodutide (BI 456906) · similar_to: Exenatide (Byetta / Bydureon) · similar_to: Liraglutide (Victoza / Saxenda) · similar_to: Dulaglutide (Trulicity) · similar_to: Semaglutide (Ozempic / Wegovy / Rybelsus) · similar_to: Fatty-acid acylated GLP-1 SAR analog	GLP-1, incretin, core
Liraglutide (Victoza / Saxenda)Verified drug	Drug	GLP-1 incretin pharmacophore	72%i	derived_from: Survodutide (BI 456906) · related_drug: Semaglutide (Ozempic / Wegovy / Rybelsus) · derived_from: GLP-1 incretin pharmacophore · similar_to: GLP-1 incretin pharmacophore · similar_to: Exenatide (Byetta / Bydureon) · similar_to: Dulaglutide (Trulicity) · similar_to: Tirzepatide (Mounjaro / Zepbound) · similar_to: Retatrutide (LY3437943) · similar_to: Survodutide (BI 456906) · similar_to: Fatty-acid acylated GLP-1 SAR analog · similar_to: Semaglutide (Ozempic / Wegovy / Rybelsus)	approved, GLP-1, peptide, obesity
OrforglipronKnown compound	Drug	GLP-1 incretin pharmacophore	8%i	derived_from: GLP-1 incretin pharmacophore · similar_to: Semaglutide (Ozempic / Wegovy / Rybelsus) · related_drug: Semaglutide (Ozempic / Wegovy / Rybelsus) · similar_to: GLP-1 incretin pharmacophore	clinical, GLP-1, oral, small-molecule
Retatrutide (LY3437943)Known compound	Drug	Tirzepatide (Mounjaro / Zepbound)	52%i	derived_from: Tirzepatide (Mounjaro / Zepbound) · related_drug: Tirzepatide (Mounjaro / Zepbound) · similar_to: GLP-1 incretin pharmacophore · similar_to: Tirzepatide (Mounjaro / Zepbound) · similar_to: Exenatide (Byetta / Bydureon) · similar_to: Liraglutide (Victoza / Saxenda) · similar_to: Dulaglutide (Trulicity) · similar_to: Semaglutide (Ozempic / Wegovy / Rybelsus) · similar_to: Survodutide (BI 456906) · similar_to: Fatty-acid acylated GLP-1 SAR analog	clinical, GLP-1, GIP, glucagon, triple-agonist
Semaglutide (Ozempic / Wegovy / Rybelsus)Verified drug	Drug	GLP-1 incretin pharmacophore	60%i	derived_from: GLP-1 incretin pharmacophore · derived_from: Tirzepatide (Mounjaro / Zepbound) · derived_from: Fatty-acid acylated GLP-1 SAR analog · similar_to: Tirzepatide (Mounjaro / Zepbound) · similar_to: Orforglipron · related_drug: Tirzepatide (Mounjaro / Zepbound) · related_drug: Liraglutide (Victoza / Saxenda) · related_drug: Orforglipron · similar_to: GLP-1 incretin pharmacophore · similar_to: Exenatide (Byetta / Bydureon) · similar_to: Dulaglutide (Trulicity) · similar_to: Retatrutide (LY3437943) · similar_to: Survodutide (BI 456906) · similar_to: Fatty-acid acylated GLP-1 SAR analog · similar_to: Liraglutide (Victoza / Saxenda)	approved, GLP-1, peptide, obesity, oral-tablet
Survodutide (BI 456906)Known compound	Drug	Liraglutide (Victoza / Saxenda)	68%i	derived_from: Liraglutide (Victoza / Saxenda) · similar_to: GLP-1 incretin pharmacophore · similar_to: Exenatide (Byetta / Bydureon) · similar_to: Liraglutide (Victoza / Saxenda) · similar_to: Dulaglutide (Trulicity) · similar_to: Semaglutide (Ozempic / Wegovy / Rybelsus) · similar_to: Tirzepatide (Mounjaro / Zepbound) · similar_to: Retatrutide (LY3437943) · similar_to: Fatty-acid acylated GLP-1 SAR analog	clinical, GLP-1, glucagon, dual-agonist
Tirzepatide (Mounjaro / Zepbound)Verified drug	Drug	Semaglutide (Ozempic / Wegovy / Rybelsus)	51%i	derived_from: Semaglutide (Ozempic / Wegovy / Rybelsus) · derived_from: Retatrutide (LY3437943) · similar_to: Semaglutide (Ozempic / Wegovy / Rybelsus) · related_drug: Semaglutide (Ozempic / Wegovy / Rybelsus) · related_drug: Retatrutide (LY3437943) · similar_to: GLP-1 incretin pharmacophore · similar_to: Retatrutide (LY3437943) · similar_to: Exenatide (Byetta / Bydureon) · similar_to: Liraglutide (Victoza / Saxenda) · similar_to: Dulaglutide (Trulicity) · similar_to: Survodutide (BI 456906) · similar_to: Fatty-acid acylated GLP-1 SAR analog	approved, GLP-1, GIP, dual-agonist, obesity

Loading map…

Clinical · regulatory context

GLP-1 / incretin — 비만·당뇨 핫사이클

Semaglutide·tirzepatide가 표준. 경구 small-mol(orforglipron)은 별도 케모타입입니다.

Approved/clinical labels here come from the catalog clinical overlay. Agency names are shown when curated; live FDA/EMA APIs are not called.

SemaglutideApprovedFDA/EMA
T2D / chronic weight management
ClinicalTrials.gov
TirzepatideApprovedFDA/EMA
T2D / obesity (dual GIP/GLP-1)
ClinicalTrials.gov
OrforglipronP3Investigational
Oral non-peptide GLP-1RA
ClinicalTrials.gov

Program and pipeline notes live on BioMoa · glp1 · StructureMoa ↔ BioMoa bridge